De-escalating DAPT to ticagrelor monotherapy cuts bleeding risk in acute coronary syndrome
For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual ...
infectiousdiseaseadvisor.com3d
FDA Drug Approval Decisions Expected in March 2025
The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...
Nature1mon
Ticagrelor in ACS—what does PLATO teach us?
The results of PLATO (A Study of Platelet Inhibition and Patient Outcomes) 1 provide a major advance in our understanding of ADP receptor inhibition with the novel agent ticagrelor. When compared ...
University of Sheffield3y
Surviving a heart attack: How ticagrelor saves lives
Ticagrelor has saved the lives of thousands of heart attack patients around the world. Its journey from discovery over twenty years ago to world-wide treatment was the product of one of the largest ...
اخبار 2413d
Saudi Chemical gets SFDA approval on pharma product
Saudi Chemical Co. Holding obtained the Saudi Food and Drug Authority’s (SFDA) approval to register Ticagrelor as a fully ...
Monthly Prescribing Reference2d
De-Escalating DAPT to Ticagrelor Monotherapy Cuts Bleeding Risk in Acute Coronary Syndrome
Yong-Joon Lee, MD, from Severance Hospital at the Yonsei University College of Medicine in Seoul, South Korea, and colleagues compared the effects of de-escalating DAPT to ticagrelor monotherapy ...